Redhill Biopharma Ltd

NASDAQ:RDHLUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Depreciation 1,445 2,136 1,914 Amortization of intangible assets 545 6,018 16,235 Gains from the transfer of rights in Movantik(R) and extinguishment of debt obligations, (see below) (56,082) -- -- Gains from early termination of leases and impairment of fixed assets, net (543) -- -- Non-cash expenses related to borrowing and payable in respect of intangible assets purchase -- 33,151 5,366 Fair value (gains) losses on derivative financial instruments and changes in royalty obligation 5,359 (13,422) 5 Loss from modification of warrants terms as part of a new issuance 1,459 -- -- Issuance costs in respect of warrants 2,034 958 -- Exchange differences and revaluation of bank deposits 19 (40) 118 --------- -------- -------- (44,117) 34,476 33,850 --------- -------- -------- Changes in assets and liability items: Decrease (increase) in trade receivables 31,930 (2,845) (3,021) Decrease in prepaid expenses and other receivables 1,586 274 860 Decrease (increase) in inventories 2,387 3,801 (8,285) Increase (decrease) in accounts payable (952) (7,434) 111 (Decrease) in accrued expenses and other liabilities (13,354) (2,947) (3,186) Increase (decrease) in allowance for deductions from revenue (37,216) 17,159 12,368 --------- -------- -------- (15,619) 8,008 (1,153) --------- -------- -------- Net cash used in operating activities (35,820) (29,185) (65,047) --------- -------- -------- INVESTING ACTIVITIES: Purchase of fixed assets (11) (198) (115) Change in investment in current bank deposits 15 8,500 (8,500) Proceeds from sale of financial assets at fair value through profit or loss -- -- 475 --------- -------- -------- Net cash provided by (used in) investing activities 4 8,302 (8,140) --------- -------- -------- FINANCING ACTIVITIES: Proceeds from issuance of ordinary shares and warrants, net of issuance costs 13,959 23,806 78,536 Exercise of options into ordinary shares -- -- 4,006 Repayment of payable in respect of intangible asset purchase (6,555) (10,878) (7,397) Decrease in restricted cash 15,210 -- -- Payment of principal with respect to lease liabilities (1,175) (1,475) (1,683) --------- -------- -------- Net cash provided by financing activities 21,439 11,453 73,462 --------- -------- -------- INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (14,377) (9,430) 275 EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS (22) (76) (96) BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 19,968 29,474 29,295 --------- -------- -------- BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF PERIOD 5,569 19,968 29,474 ========= ======== ======== SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH 138 84 47 --------- -------- -------- SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH 367 8,182 11,280 --------- -------- -------- SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING AND FINANCING ACTIVITIES: Acquisition of right-of-use assets by means of lease liabilities 270 5,590 303 --------- -------- -------- Decrease in lease liability (with corresponding decrease in right of use asset in amount of $4,697 in 2023 and $534 in 2022) resulting from early termination of lease. 5,413 587 -- --------- -------- -------- Transfer of rights in Movantik(R) and extinguishment of debt obligations: Decrease in Intangible asset (59,503) Decrease in Inventories (4,233) Decrease in Payable in respect of Intangible asset 4,602 Decrease in Borrowing 115,216 --------- Gains from the transfer of the rights in Movantik(R) and extinguishment of debt obligations 56,082 =========